Literature DB >> 15749704

AP2 clathrin adaptor complex, but not AP1, controls the access of the major histocompatibility complex (MHC) class II to endosomes.

Marc Dugast1, Hélène Toussaint, Christelle Dousset, Philippe Benaroch.   

Abstract

Newly synthesized MHC II alpha- and beta-chains associated with the invariant chain chaperone (Ii) enter the endocytic pathway for Ii degradation and loading with peptides before transport to the cell surface. It is unclear how alphabetaIi complexes are sorted from the Golgi apparatus and directed to endosomes. However, indirect evidence tends to support direct transport involving the AP1 clathrin adaptor complex. Surprisingly, we show here that knocking down the production of AP1 by RNA interference did not affect the trafficking of alphabetaIi complexes. In contrast, AP2 depletion led to a large increase in surface levels of alphabetaIi complexes, inhibited their rapid internalization, and strongly delayed the appearance of mature MHC II in intracellular compartments. Thus, in the cell systems studied here, rapid internalization of alphabetaIi complexes via an AP2-dependent pathway represents a key step for MHC II delivery to endosomes and lysosomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749704     DOI: 10.1074/jbc.M501357200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

3.  Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments.

Authors:  Andrés Finzi; Alexandre Brunet; Yong Xiao; Jacques Thibodeau; Eric A Cohen
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.

Authors:  Scott H Coleman; Ricardo Madrid; Nanette Van Damme; Richard S Mitchell; Jerome Bouchet; Cecile Servant; Satish Pillai; Serge Benichou; John C Guatelli
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Novel regulation of MHC class II function in B cells.

Authors:  Yohei Matsuki; Mari Ohmura-Hoshino; Eiji Goto; Masami Aoki; Mari Mito-Yoshida; Mika Uematsu; Takanori Hasegawa; Haruhiko Koseki; Osamu Ohara; Manabu Nakayama; Kiminori Toyooka; Ken Matsuoka; Hak Hotta; Akitsugu Yamamoto; Satoshi Ishido
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

6.  The chondroitin sulfate form of invariant chain trimerizes with conventional invariant chain and these complexes are rapidly transported from the trans-Golgi network to the cell surface.

Authors:  Lynne S Arneson; Jim Miller
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

Review 7.  MHC class II transport at a glance.

Authors:  Adam C Berger; Paul A Roche
Journal:  J Cell Sci       Date:  2009-01-01       Impact factor: 5.285

Review 8.  MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.

Authors:  Toine ten Broeke; Richard Wubbolts; Willem Stoorvogel
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

9.  Internalizing MHC class II-peptide complexes are ubiquitinated in early endosomes and targeted for lysosomal degradation.

Authors:  Kazuyuki Furuta; Even Walseng; Paul A Roche
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

10.  Multiple dileucine-like motifs direct VGLUT1 trafficking.

Authors:  Sarah M Foss; Haiyan Li; Magda S Santos; Robert H Edwards; Susan M Voglmaier
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.